S. Anguille, V. F. Van-tendeloo, and Z. N. Berneman, Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia, Leukemia, vol.26, pp.2186-2196, 2012.

R. Assi, H. Kantarjian, F. Ravandi, and N. Daver, Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors, Curr Opin Hematol, vol.25, pp.136-114, 2018.

D. B. Rubinstein, M. Karmely, and E. Pichinuk, The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/ beta junction mediates cell killing, Int J Cancer, vol.124, pp.46-54, 2009.

S. Cloosen, J. Gratama, and E. B. Van-leeuwen, Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma, Br J Haematol, vol.135, pp.513-516, 2006.

F. Levitin, O. Stern, and M. Weiss, The MUC1 SEA module is a self-cleaving domain, J Biol Chem, vol.280, pp.33374-33386, 2005.

D. W. Kufe, Mucins in cancer: function, prognosis and therapy, Nat Rev Cancer, vol.9, pp.874-885, 2009.

D. B. Rubinstein, M. Karmely, and R. Ziv, MUC1/X protein immunization enhances cDNA immunization in generating antiMUC1 alpha/beta junction antibodies that target malignant cells, Cancer Res, vol.66, pp.11247-11253, 2006.

E. Pichinuk, I. Benhar, and O. Jacobi, Antibody targeting of cellbound MUC1 SEA domain kills tumor cells, Cancer Res, vol.72, pp.3324-3336, 2012.

D. A. Arber, A. Orazi, and R. Hasserjian, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, pp.2391-2405, 2016.

P. X. Xing, J. J. Tjandra, and K. Reynolds, Reactivity of antihuman milk fat globule antibodies with synthetic peptides, J Immunol, vol.142, pp.3503-3509, 1989.

M. R. Price, P. D. Rye, and E. Petrakou, Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin, Tumour Biol, vol.19, issue.1, pp.1-20, 1996.

D. Selimoglu-buet, O. Wagner-ballon, and V. Saada, Francophone Myelodysplasia Group. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia, Blood, vol.125, pp.3618-3626, 2015.

W. Gorczyca, Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AMLM5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML), Methods Cell Biol, vol.75, pp.665-677, 2004.

C. Lacronique-gazaille, M. P. Chaury, L. Guyader, A. Faucher, J. L. Bordessoule et al., A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML, Haematologica, vol.92, pp.859-860, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00451224

Y. Xu, R. W. Mckenna, N. J. Karandikar, A. J. Pildain, and S. H. Kroft, Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis, Am J Clin Pathol, vol.124, pp.799-806, 2005.

M. A. Lyu, Y. J. Cao, K. A. Mohamedali, and M. G. Rosenblum, Cell-targeting fusion constructs containing recombinant gelonin, Methods Enzymol, vol.502, pp.167-214, 2012.

H. D?-ohner, E. Estey, and D. Grimwade, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, pp.424-447, 2017.

M. E. Verhoeyen, J. A. Saunders, and M. R. Price, Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody, Immunology, vol.78, pp.364-370, 1993.

R. H. Verheijen, L. F. Massuger, and B. B. Benigno, Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission, J Clin Oncol, vol.24, pp.571-578, 2006.

G. Rivalland, B. Loveland, and P. Mitchell, Update on Mucin-1 immunotherapy in cancer: a clinical perspective, Expert Opin Biol Ther, vol.15, pp.1773-1787, 2015.

J. Taylor-papadimitriou, J. M. Burchell, R. Graham, and R. Beatson, Latest developments in MUC1 immunotherapy, Biochem Soc Trans, vol.46, pp.659-668, 2018.

C. F. Leong, O. Raudhawati, S. K. Cheong, K. Sivagengei, N. Hamidah et al., Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts, Pathology, vol.35, pp.422-427, 2003.

M. Wykes, K. P. Macdonald, and M. Tran, MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells, J Leukoc Biol, vol.72, pp.692-701, 2002.

S. Cloosen, M. Thio, and A. Vancl-ee, Mucin-1 is expressed on dendritic cells, both in vitro and in vivo, Int Immunol, vol.16, pp.1561-1571, 2004.

G. Pentheroudakis, V. Malamou-mitsi, and E. Briasoulis, The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy, Cancer, vol.101, pp.1767-1775, 2004.

S. Fatrai, H. Schepers, H. Tadema, E. Vellenga, S. Daenen et al., Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases, Exp Hematol, vol.36, pp.1254-1265, 2008.

D. Stroopinsky, J. Rosenblatt, and K. Ito, MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells, Cancer Res, vol.73, pp.5569-5579, 2013.

P. Brossart, A. Schneider, and P. Dill, The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes, Cancer Res, vol.61, pp.6846-6850, 2001.

R. Itzykson, P. Fenaux, and E. Solary, Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative, Best Pract Res Clin Haematol, vol.26, pp.387-400, 2013.

M. M. Patnaik, S. A. Parikh, C. A. Hanson, and A. Tefferi, Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review, Br J Haematol, vol.165, pp.273-286, 2014.

M. L. Loh, Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia, Br J Haematol, vol.152, pp.677-687, 2011.

E. Solary and R. Itzykson, How I treat chronic myelomonocytic leukemia, Blood, vol.130, pp.126-136, 2017.

D. Thomas and R. Majeti, Biology and relevance of human acute myeloid leukemia stem cells, Blood, vol.129, pp.1577-1585, 2017.

V. H. Van-der-velden, N. Boeckx, and I. Jedema, High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients, Leukemia, vol.18, pp.983-988, 2004.

A. S. Wayne, D. J. Fitzgerald, R. J. Kreitman, and I. Pastan, Immunotoxins for leukemia, Blood, vol.123, pp.2470-2477, 2014.

J. R. Mccombs and S. C. Owen, Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry, AAPS J, vol.17, pp.339-351, 2015.

F. Stirpe, S. Olsnes, and A. Pihl, Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A, J Biol Chem, vol.255, pp.6947-6953, 1980.

P. Chevallier, J. Delaunay, and P. Turlure, Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33( + ) primary resistant or relapsed acute myeloid leukemia, J Clin Oncol, vol.26, pp.5192-5197, 2008.

S. Castaigne, C. Pautas, and C. Terr-e, Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, Lancet, vol.379, pp.1508-1516, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01016571

G. Borthakur, M. G. Rosenblum, and M. Talpaz, Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies, Haematologica, vol.98, pp.217-221, 2013.

S. Schiffer, R. Rosinke, and E. Jost, Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins, Int J Cancer, vol.135, pp.1497-1508, 2014.